Suppr超能文献

[靶向小鼠肝细胞系AML12中miR-101a基因的一体化CRISPR/Cas9载体系统的构建]

[Construction of all-in-one CRISPR/Cas9 vector system targeting miR-101a gene in mouse hepatic cell line AML12].

作者信息

Chen Dahua, Li Youming

机构信息

Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

出版信息

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2017 Jul 25;46(4):427-432. doi: 10.3785/j.issn.1008-9292.2017.08.13.

Abstract

OBJECTIVE

To develop an all-in-one CRISPR/Cas9 vector system that can efficiently knockdown miR-101a expression in mice.

METHODS

Three sgRNAs targeting mouse miR-101a gene and a small guide (sgRNA) targeting green fluorescent protein gene were designed and constructed into an all-in-one vector system (pENTRY-U6-sgRNA-WT Cas9). Moreover, sgRNA1 and sgRNA3 were selected and constructed into a double-nicking Cas9 vector (pENTRY-U6-sgRNA-U6-sgRNA-Cas9 D10A). The constructed plasmids were transfected into mouse liver AML12 cells for validation by T7 EndoⅠ(T7EⅠ) 72 h after transfection. The pAD vectors were cloned via the Gateway system, and the recombinant adenovirus vectors were packaged in 293A cells. The virus particles were used to infect AML12 cells and the expression levels of mature miR-101a were analyzed to monitor the knockout efficiency after 72 h.

RESULTS

The constructed pENTRY all-in-one vectors were validated by gene sequencing and T7EⅠ assay, which showed CRISPR/Cas9-mediated mismatches at target sites of miR-101a gene. The adenovirus vectors were constructed successfully. The CRISPR/Cas9 containing adenovirus was introduced to AML12 cells and the quantitative real-time PCR assays indicated that the expression level of mature miR-101a was significantly decreased compared with that of the control (all <0.01).

CONCLUSIONS

We have successfully constructed two "all-in-one" CRISPR/Cas9 vector systems targeting miR-101a gene in mouse liver AML12 cells with high efficiency. It provides experimental basis for research of microRNA, and a reference method for knockout of other miRNAs.

摘要

目的

开发一种一体化的CRISPR/Cas9载体系统,该系统能够有效地敲低小鼠体内miR-101a的表达。

方法

设计靶向小鼠miR-101a基因的3条sgRNA以及靶向绿色荧光蛋白基因的1条小向导RNA(sgRNA),并构建到一体化载体系统(pENTRY-U6-sgRNA-WT Cas9)中。此外,选取sgRNA1和sgRNA3构建到双切口Cas9载体(pENTRY-U6-sgRNA-U6-sgRNA-Cas9 D10A)中。将构建好的质粒转染到小鼠肝脏AML12细胞中,转染72小时后通过T7内切酶Ⅰ(T7EⅠ)进行验证。通过Gateway系统克隆pAD载体,并在293A细胞中包装重组腺病毒载体。用病毒颗粒感染AML12细胞,并分析成熟miR-101a的表达水平,以监测72小时后的敲除效率。

结果

通过基因测序和T7EⅠ分析对构建的pENTRY一体化载体进行验证,结果显示在miR-101a基因的靶位点存在CRISPR/Cas9介导的错配。成功构建了腺病毒载体。将含有CRISPR/Cas9的腺病毒导入AML12细胞,定量实时PCR分析表明,与对照组相比,成熟miR-101a的表达水平显著降低(均<0.01)。

结论

我们成功地在小鼠肝脏AML12细胞中高效构建了两种靶向miR-101a基因的“一体化”CRISPR/Cas9载体系统。这为微小RNA的研究提供了实验依据,也为敲除其他微小RNA提供了参考方法。

相似文献

2
[Effect of MiR-155 Knockout Mediated by Dual sgRNAs on Drug Sensitivity of FLT3-ITDAML].双sgRNAs介导的MiR-155敲除对FLT3-ITD AML药物敏感性的影响
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Apr;30(2):334-340. doi: 10.19746/j.cnki.issn.1009-2137.2022.02.002.

本文引用的文献

9
Genome-wide epigenetic regulation of miRNAs in cancer.癌症中 miRNA 的全基因组表观遗传调控。
Cancer Res. 2013 Jan 15;73(2):473-7. doi: 10.1158/0008-5472.CAN-12-3731. Epub 2013 Jan 10.
10
RNA-guided human genome engineering via Cas9.通过 Cas9 进行 RNA 引导的人类基因组工程。
Science. 2013 Feb 15;339(6121):823-6. doi: 10.1126/science.1232033. Epub 2013 Jan 3.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验